{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:44:37Z","timestamp":1785545077204,"version":"3.56.0"},"reference-count":36,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Patients with cancer often face significant financial challenges, known as financial toxicity (FT), which is associated with reduced quality of life. Patients with hematologic malignancies (HMs) are especially vulnerable due to intensive and prolonged treatments, frequent hospital visits, and a high risk of complications. While FT affects many in the general population, it is particularly severe among racial and ethnic minorities, especially those below the poverty line. To our knowledge, no studies have specifically examined FT in this vulnerable group in the United States.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to evaluate the severity of FT in patients receiving treatment for HMs in a socioeconomically underserved population, explore sociodemographic factors that may predict the severity of FT, and evaluate the subjective experiences of these patients as they relate to FT.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a prospective, observational, longitudinal study at the Montefiore Cancer Center\u2019s outpatient department in the Bronx, New York, from October 1, 2022, to October 30, 2023. Participants included either adult patients newly diagnosed (ND) with HMs or those already diagnosed, undergoing cellular therapy (CT). The severity of FT was assessed using the validated Comprehensive Score for Financial Toxicity\u2013Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire. Additionally, an investigator-designed questionnaire was developed to gather sociodemographic data and evaluate the subjective effects of financial burden on patient care. Patients in both the ND and CT groups were followed for 90 days. Data collection occurred at their initial presentation, as well as on days 30 and 90.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Ninety patients participated in the study (ND=52 and CT=38). The median age was 59 (IQR 44-66) years, with 27% (n=24) African American and 55% (n=48) Hispanic. Overall, 75% (n=67) of participants experienced some degree of FT, most with mild FT at baseline (day 0, median COST-FACIT score=19.4). In the CT group, FT worsened significantly over time, with a decline in median COST-FACIT scores from 19.9 at day 0 to 15.5 on day 90 (\n P<\/jats:italic>\n =.02). In a multivariable linear regression model, race and ethnicity were a significant predictor of FT burden: identifying as African American or Hispanic was associated with a significantly lower COST-FACIT score (ie, higher FT) compared to non-Hispanic White participants (B=\u22123.08,\n P<\/jats:italic>\n =.04, 95% CI \u22126.05 to \u22120.12). Additionally, over half of ND and CT participants reported difficulty affording basic necessities (ND: 28\/52, 54%; CT: 23\/38, 61%) and concerns regarding transportation access and costs (ND: 26\/50, 52%; CT: n=18\/38, 47%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n FT is prevalent among patients with HMs receiving care in underserved populations, and the burden is significantly higher among African American and Hispanic populations.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/68101","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T21:24:21Z","timestamp":1767734661000},"page":"e68101-e68101","source":"Crossref","is-referenced-by-count":1,"title":["Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-2242","authenticated-orcid":false,"given":"Lemchukwu","family":"Amaeshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1749-5404","authenticated-orcid":false,"given":"Lauren","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8876-8926","authenticated-orcid":false,"given":"Kateryna","family":"Fedorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7839-1037","authenticated-orcid":false,"given":"Alex","family":"Sisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3239-0078","authenticated-orcid":false,"given":"David","family":"Levitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0008-8392","authenticated-orcid":false,"given":"Rosmi","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-8876","authenticated-orcid":false,"given":"Dennis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-173X","authenticated-orcid":false,"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-5767","authenticated-orcid":false,"given":"Ioannis","family":"Mantzaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-4470","authenticated-orcid":false,"given":"R Alejandro","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-1167","authenticated-orcid":false,"given":"Kira","family":"Gritsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9781-8049","authenticated-orcid":false,"given":"Ridhi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-2011","authenticated-orcid":false,"given":"Noah","family":"Kornblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3569-0250","authenticated-orcid":false,"given":"Chenxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9651-7124","authenticated-orcid":false,"given":"Mimi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-1673","authenticated-orcid":false,"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-5659","authenticated-orcid":false,"given":"Bruce","family":"Rapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-8288","authenticated-orcid":false,"given":"Aditi","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-6745","authenticated-orcid":false,"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"1","key":"R1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"R2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience","volume":"18","author":"Zafar","journal-title":"Oncologist"},{"issue":"2","key":"R3","doi-asserted-by":"publisher","DOI":"10.3390\/nursrep15020067","article-title":"Financial toxicity and its association with the quality of life of Greek patients with cancer: a cross-sectional study","volume":"15","author":"Pitis","journal-title":"Nurs Rep"},{"issue":"3","key":"R4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/ajco.13448","article-title":"Financial toxicity in patients with cancer attending a public Australian tertiary hospital: a pilot study","volume":"17","author":"McLean","journal-title":"Asia Pac J Clin Oncol"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1590\/1518-8345.6688.3995","article-title":"Quality of life and financial toxicity of hematopoietic stem cell transplant recipients in COVID-19","volume":"31","author":"Oshiro","journal-title":"Rev Lat Am Enfermagem"},{"key":"R6","unstructured":"Fitch K Ferro C Pittinger S . The cost burden of blood cancer care in medicare. The Leukemia & Lymphoma Society; 2019. URL: https:\/\/us.milliman.com\/en\/insight\/the-cost-burden-of-blood-cancer-care-in-medicare [Accessed 10-01-2024]"},{"issue":"14","key":"R7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2217\/fon.14.130","article-title":"The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature","volume":"10","author":"Bestvina","journal-title":"Future Oncol"},{"key":"R8","unstructured":"Dieguez G Ferro C Rotter D . The cost burden of blood cancer care. The Leukemia & Lymphoma Society; 2018. URL: https:\/\/us.milliman.com\/en\/insight\/the-cost-burden-of-blood-cancer-care [Accessed 10-01-2024]"},{"issue":"4","key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00671-z","article-title":"Financial toxicity in hematological malignancies: a systematic review","volume":"12","author":"Ouchveridze","journal-title":"Blood Cancer J"},{"issue":"3","key":"R10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","article-title":"A systematic review of financial toxicity among cancer survivors: we can\u2019t pay the co-pay","volume":"10","author":"Gordon","journal-title":"Patient"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/jso.25374","article-title":"Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies","volume":"120","author":"Lentz","journal-title":"J Surg Oncol"},{"key":"R12","unstructured":"The Bronx neighborhood profile. NYU Furman Center. URL: https:\/\/furmancenter.org\/neighborhoods\/view\/the-bronx [Accessed 01-09-2023]"},{"issue":"3","key":"R13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the Comprehensive Score for Financial Toxicity (COST)","volume":"123","author":"de Souza","journal-title":"Cancer"},{"issue":"22","key":"R14","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","volume":"2","author":"Jain","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"R15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood-2021-146032","article-title":"Worsening financial toxicity among patients receiving chimeric antigen receptor t-cell (CAR-T) therapy: a mixed methods longitudinal study","volume":"138","author":"Cusatis","journal-title":"Blood"},{"issue":"5","key":"R16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/bloodadvances.2023011033","article-title":"Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective","volume":"8","author":"Maziarz","journal-title":"Blood Adv"},{"issue":"7","key":"R17","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/bmt.2009.330","article-title":"Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes","volume":"45","author":"McDiarmid","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"R18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bbmt.2012.10.011","article-title":"Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease","volume":"19","author":"Ringd\u00e9n","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"R19","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/tbm\/ibab091","article-title":"Financial toxicity in cancer care: origins, impact, and solutions","volume":"11","author":"Abrams","journal-title":"Transl Behav Med"},{"issue":"2","key":"R20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55388","article-title":"Financial toxicity among patients with breast cancer worldwide","volume":"6","author":"Ehsan","journal-title":"JAMA Netw Open"},{"issue":"12","key":"R21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","article-title":"Distance as a barrier to cancer diagnosis and treatment: review of the literature","volume":"20","author":"Ambroggi","journal-title":"Oncologist"},{"issue":"9","key":"R22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/OP.22.00122","article-title":"The road less traveled: transportation barriers to cancer care delivery in the rural patient population","volume":"18","author":"Wercholuk","journal-title":"JCO Oncol Pract"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00120","article-title":"Financial toxicity in adults with cancer: adverse outcomes and noncompliance","author":"Knight","journal-title":"J Oncol Pract"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1200\/OP.21.00440","article-title":"Association of race with cancer-related financial toxicity","volume":"18","author":"Panzone","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"R25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","article-title":"Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors","volume":"34","author":"Yabroff","journal-title":"J Clin Oncol"},{"issue":"8","key":"R26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/cncr.29206","article-title":"Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer?","volume":"121","author":"Pisu","journal-title":"Cancer"},{"key":"R27","unstructured":"County B. Bronx borough health equity report 2021. 2021. URL: https:\/\/www.cdc.gov\/minorityhealth\/index.html [Accessed 20-11-2025]"},{"key":"R28","unstructured":"Frieden TR . Health care access among adults in New York city. The importance of having insurance and a regular care provider. New York City Department of Health and Mental Hygiene; 2007. URL: https:\/\/www.commonwealthfund.org\/sites\/default\/files\/documents\/___media_files_resources_2007_new_report_examines_new_yorkers_access_to_care_access_dohmh_for_web_pdf.pdf [Accessed 10-01-2024]"},{"issue":"2","key":"R29","first-page":"80","volume":"27","author":"Zafar","journal-title":"Oncology (Williston Park)"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Davis MP . Cancer pain. In: The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer International Publishing; 2018:17-35. [doi: 10.1007\/978-3-319-90990-5_2]","DOI":"10.1007\/978-3-319-90990-5_2"},{"issue":"9","key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2022.04.008","article-title":"Financial toxicity and psychological distress in adults with cancer: a treatment-based analysis","volume":"9","author":"Yu","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"2","key":"R32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21443","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"R33","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"R34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/JCO.19.01564","article-title":"Understanding financial hardship among cancer survivors in the United States: strategies for prevention and mitigation","volume":"38","author":"Yabroff","journal-title":"J Clin Oncol"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50211","article-title":"Estimated indirect cost savings of using telehealth among nonelderly patients with cancer","volume":"6","author":"Patel","journal-title":"JAMA Netw Open"},{"issue":"21","key":"R36","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1200\/JCO.21.02184","article-title":"Financial navigation in cancer care delivery: state of the evidence, opportunities for research, and future directions","volume":"40","author":"Offodile","journal-title":"J Clin Oncol"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e68101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:27:21Z","timestamp":1785536841000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e68101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":36,"URL":"https:\/\/doi.org\/10.2196\/68101","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"v12i1e68101"}}